Navigation Links
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
Date:1/22/2009

IRVINE, Calif., Jan. 22 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive results from the Company's Phase IIb clinical study of ecabet sodium, which is being developed as a treatment for dry eye disease. Patients treated with ecabet sodium achieved a strong positive trend in the objective sign of Tear Film Break-Up Time (TFBUT) and a positive trend in the objective sign of quantity of tears produced (Schirmer Test). In contrast, there were no trends seen in the placebo group for either objective sign. In addition, there were no trends seen in either group in subjective symptoms as measured by the Ocular Surface Disease Index (OSDI) or patient's worst reported symptom. In Phase II tests where observations are not powered to show statistical significance, strong and positive trends are used as indicators of potential efficacy in subsequent Phase III studies.

"The Phase IIb results from this environmental study add further support to our belief that ecabet sodium has the ability to treat signs and symptoms of dry eye syndrome. Ecabet sodium may provide advantages over other products used to treat dry eye and those that are in development, as we believe ecabet sodium not only improves the quality of tears but also increases the quantity of tears," stated Vicente Anido Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "After reviewing the guidance from and our discussions with the FDA, we believe that by conducting two successful Phase III environmental clinical trials for improvement in signs and two successful Phase III controlled chamber clinical trials for the improvement of symptoms, we should receive marketing approval. In addition, we are expecting results from a Phase II clinical trial studying the potential of a lower strength of Xibrom to treat the signs and symptoms
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
6. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
7. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  ACI Clinical ( www.aciclinical.com ) ... Monitoring Committees. Using this solution, trial ... industry standard costs and receive the same expertise ... committee services. Leveraging a decade of ... charter development, statistical programming and meeting facilitation), ACI ...
(Date:8/21/2014)... Aug. 21, 2014  AliveCor, Inc. announced ... Administration (FDA) has granted the company clearance ... (AFib), the most common form of cardiac ... detects if patients are experiencing AFib through ... mobile phone based AliveCor® Heart Monitor, so ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., previously ... members to its Board of Directors, enhancing executive ... the company, a leading licensed producer of medicinal ... Bedrocan has 13 years, experience in producing and ... countries, including Canada. As previously ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3
... Inc. (Nasdaq: VNDA ), announced today that ... for tasimelteon, an oral dual melatonin receptor agonist in ... in blind individuals with no light perception. This follows ... for Orphan Medicinal Products (COMP) of the European Medicines ...
... 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), ... president and chief executive officer, is scheduled to present at ... 17, 2011, at 9:30 a.m. EDT being held at the ... to present an overview of the company. A ...
Cached Medicine Technology:Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4
(Date:8/22/2014)... The leather seat covers provided by Lseat.comare ... meet customers’specific product needs. Recently, the company has unveiled its ... , The company wants to provide worldwide clients with more ... cover industry for a long time. According to the company’s ... promotional rates. Among all the new products, Chevrolet Camaro ...
(Date:8/22/2014)... NY (PRWEB) August 22, 2014 ... Chinese orthopedic instrument industry, some foreign and domestic ... instrument market though mergers and acquisitions. In 2012, ... maker in China-- China Kanghui Holdings for USD ... China’s largest trauma product makers-- Trauson Holdings Company ...
(Date:8/22/2014)... Dallas, Texas (PRWEB) August 22, 2014 ... from $297 million in 2013 to $407 million by ... 6.59%. The company’s latest report “OpportunityAnalyzer Graft-Versus-Host Disease – ... growth, which will occur over six major markets (6MM: ... will be strongest in the five European countries (5EU), ...
(Date:8/22/2014)... Tug McGraw Foundation and Team McGraw is partnering with ... the 39th Annual Marine Corps Marathon on October 26, 2014. ... in coaching, training and participation for the 26.2-mile course that ... and is often referred to as the Marathon of the ... the largest marathon in the world that does not offer ...
(Date:8/22/2014)... AttorneyOne.com, a recognized authority on law, ... from the FDA on Diamondback 360 Peripheral Orbital ... on August 19, that certain lots of the Diamondback ... number 7-10003), by Cardiovascular Systems, are recalled ... fracture during use and could possibly block blood vessels. ...
Breaking Medicine News(10 mins):Health News:Custom 1993-1996 Chevrolet Camaro Leather Seat Covers Now for Sale at Lseat.com 2Health News:China Orthopedic Instrument Industry 2014- Global Industry Size, Share, Trend, Growth and Forecast 2017 2Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Tug McGraw Foundation and Team Red White and Blue Join to Run in Marine Corps Marathon 2Health News:Tug McGraw Foundation and Team Red White and Blue Join to Run in Marine Corps Marathon 3Health News:Diamondback 360 Peripheral Orbital Atherectomy System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2
... But anxiety could be helpful in long run, researchers note ... that worrying about something before it happens might do more ... that people who seemed to have higher levels of "anticipatory ... part of the brain known as the anterior insula -- ...
... Schering-Plough,Corporation (NYSE: SGP ) announced today a ... executives with the interests of shareholders., "We ... believe are,now among the strongest in our industry, ... executives)," said Hans W. Becherer,Chairman of the Compensation ...
... CEO of new charity, LONG BEACH, Calif., April ... a new $205-million charitable foundation that will,focus on innovative ... SCAN Foundation," the new organization will become,when fully operational, ... of the elderly., SCAN also announced the appointment ...
... The warmer months entice,people of all ages to ... need,to be reminded about the importance of sun protection. ... dozens of simple ways to change skin,cancer prevention from ... M.D., associate professor in the Department of,Dermatology at The ...
... of biological pathways could lead to treatments for other ... Researchers have discovered seven common DNA variations that increase ... which links the skin condition and psoriatic arthritis to ... 4 in the open-access journal PLoS Genetics , ...
... better-educated communities have more facilities offering the end-of-life care, ... More than one-third of Americans are now getting hospice ... isn,t available to many people in the country, a ... incomes and education levels, and those with sizeable elderly ...
Cached Medicine News:Health News:'Worry' Spot in Brain Found 2Health News:Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management 2Health News:SCAN Health Plan Announces Creation of $205 Million Foundation Dedicated to the Needs of Seniors 2Health News:Outsmart the Summer Sun at Any Age 2Health News:Researchers Identify New Genetic Links to Psoriasis 2Health News:While Hospice Care Is Growing, Not All Have Access 2Health News:While Hospice Care Is Growing, Not All Have Access 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: